A modified double blind crossover study was performed to assess the effect of 1% topical minoxidil as compared with placebo in 30 patients with alopecia areata and alopecia totalis. The active preparation produced a highly significant incidence of hair regrowth. A cosmetically acceptable response was noted in 16 patients. No side effects were seen.
Introduction
Many drugs may cause hypertrichosis'; in some, such as the psoralens and benoxaprofen, the mechanism is probably phototoxic, whereas in others it may be due to hormonal modulation or vasodilatation. In most cases, however, the mechanism is unknown.
Minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxide) is a potent oral vasodilator which acts directly on vascular smooth muscle and is usually reserved for resistant hypertension. Given systemically it appears to be one of the few drugs capable of converting vellus to terminal hair.2 Hypertrichosis occurs in practically all patients treated with minoxidil3; the increased hair growth usually affects the forehead, temples, eyebrows, forearms, and even the nose. 4 In 1980 Zappacosta reported reversal of male pattern alopecia in a patient receiving oral minoxidil for hypertension.5 Isolated case reports subsequently suggested that minoxidil applied as a topical agent might be efficacious in alopecia areata.5 6 In view of the unpredictable course of alopecia areata and its tendency for natural resolution we carried out a modified double blind crossover trial to assess the effects of topical minoxidil and placebo in patients suffering from alopecia areata and alopecia totalis.
Patients and methods
Thirty patients with alopecia areata were studied. They consisted of patients already being seen as outpatients and an uninterrupted sequence of patients attending the outpatient department. Ages ranged from 6 to 85 years (median 43-4 years); 13 were female and 17 male. The age at onset of alopecia ranged from 2 to 85 years (median 30-2 years), and the total duration of disease before entry to the trial ranged from three months to 42 years (median 5 years). Most of the patients had extensive patchy alopecia areata, three had ophiasis pattern, and nine had alopecia totalis or universalis.
Patients were allocated to one of four treatment groups: (1) active ointment, (2) placebo ointment, (3) active lotion, (4) placebo lotion. All four preparations were made on a one off dispensing basis to the following formulas7: (1) 1% minoxidil ointment-ground minoxidil tablets 10 mg x 20, Unguentum Merck to 20 g; (2) placebo ointmentlactose 2-5 g, Unguentum Merck to 20 g; (3) 1% minoxidil lotionground minoxidil tablets 10 mg x 20, propylene glycol 2 ml, distilled water 4 ml, industrial spirit 95% to 20 ml; (4) placebo lotionlactose 2-5 g, propylene glycol 2 ml, distilled water 4 ml, industrial spirit 95%/ to 20 ml. figure) . Three patients withdrew after three months; all had been allocated placebo, and none had regrowth of hair. One patient had complete spontaneous hair regrowth while receiving placebo.
In the active ointment group the two non-responders were both atopics with alopecia universalis. Of the non-responders in the active lotion group, one had alopecia universalis and one alopecia totalis.
Regrowth of eyelashes and eyebrows occurred in three patients Although it would be easy to accept that the mechanism of action of hair regrowth seen with topical minoxidil might be due to vasodilatation, control studies using topical glyceryl trinitrate have failed to produce hair regrowth, suggesting that arteriolar rather than venular dilatation is required. Hair regrowth at sites distant to those treated (eyebrows and eyelashes in three patients) might also be due to a systemic effect of absorbed minoxidil,1 but similar observations have been made in patients with alopecia areata treated with local 2,4-dinitrochlorobenzene and primula sensitisation. The hypertrichosis does not appear to be hormonal in origin since plasma testosterone and urinary hydroxysteroid and ketosteroid concentrations are normal during minoxidil treatment, thereby excluding androgenic stimulation.'2 13 Microscopical examination of hair grown during systemic treatment with minoxidil shows an intermediate type of hair with pigmentation and intermittent medullation and a normal shaft.4 Some of the hairs grown during treatment with topical minoxidil were classified as intermediate in type, being longer than vellus hair but too fine and thin to be terminal hair (table III) . Some patients' regrowth never progressed beyond this intermediate phase and was not cosmetically acceptable, while others went on to develop terminal hair.
Although we have little doubt that topical minoxidil can induce new hair growth in patients suffering from alopecia areata, those with more severe and extensive disease have a worse response and those with alopecia universalis and alopecia totalis are less liIrely to respond. It is not possible at this stage to say whether treatment with minoxidil will affect eventual prognosis. The few post-treatment biopsies that we have performed suggest that the disease is still active despite regrowth of hair. Only time will tell whether this treatment will find an established place in the management of patients with alopecia areata or whether hair that has regrown will be retained when treatment is discontinued. Topical minoxidil, however, appears to have at least two virtues: firstly, it now appears clear that it can induce some hair regrowth and may be a useful stopgap measure in patients suffering from alopecia areata, to see them through until spontaneous resolution occurs; and, secondly, it appears to be relatively safe, with no topical or systemic side effects having been encountered during this study.
Introduction
Veterinary surgeons are likely to be more than usually exposed to the viruses that cause Marek's disease, feline lymphomas, bovine lymphosarcoma, and other animal tumours. If 
